Sign in
Not yet taking people in United StatesPhase 2

Scan imaging in adults with dermatomyositis that has not responded to treatment

Tests a scan tracer, [18F]-FAPI-74, in adults with refractory dermatomyositis.

Key facts

Who runs it
Farshad Moradi
Where
Stanford, United StatesSee the site
Trial code
Registry title
Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging
Status
Not yet recruiting
Phase
Phase 2
People taking part
21 people, planned
Started
Dec 2024
Expected to end
Oct 2028
Type of study
Interventional
Treatments tested
  • [18F]-FAPI-74
Record updated
29 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with suspected dermatomyositis, an inflammatory muscle and skin disease, that is hard to treat. Participants get a [18F]-FAPI-74 injection followed by PET/MRI scans.

Age
Older than 18 years.
Sex
All sexes can join.
Disease stage
Suspected dermatomyositis. The title describes it as refractory, meaning it does not respond well to treatment.

Main reasons for not taking part

  • Women who are pregnant or may be pregnant.
  • People who cannot have an MRI scan.
  • People who cannot lie flat for 30 min.
  • Any serious medical condition that the lead doctor thinks makes taking part too risky.

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients with suspected dermatomyositis
  • Patient must be > 18 years old
  • Be willing and able to provide written informed consent for the trial

Who cannot take part

  • Any serious medical condition that in the opinion of principal investigator could pose significant risk of harm or injury to the patient if they participate in the study
  • Women who are pregnant or potentially pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women
  • Contraindication to MRI or inability to lie flat for 30 min

Where in United States

  • Stanford UniversityStanford, United StatesNot yet recruiting

About the trial

What the trial wants to find out

This study proposes the use of a PET isotope, [18F]-Fibroblast Activation Protein Inhibitor-74, for a prospective single-center, single-arm study using MRI imaging for participants with Refractory Dermatomyostitis.

The group in the trial

  • [18F]-FAPI-74 PET/ MRITreatment being tested

    Participant receive \[18F\]-FAPI-74 injection and approximately 45-60 minutes later receive a MRI scan from vertex to legs, followed by a static PET emission scan over the same area.

    Treatment: [18F]-FAPI-74

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Evaluation of Patients With Refractory Dermatomyositis Using [18F]- Fibroblast Activation Protein Inhibitor-74 (FAPI-74) PET/MRI Imaging
Plain-language title
Scan imaging in adults with dermatomyositis that has not responded to treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
29 November 2024